Argent Biopharma Ltd (ASX:RGT) Share Price

Company Profile

Business description
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Contact
295 Rokeby Road
Suite 1
SubiacoWA6008
AUS
T: +61 865552950
E: [email protected]
https://www.argentbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees

Recommended

Our coverage remains overvalued.

Jon Mills, CFA | 14 January 2026

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

William Kerwin, CFA | 12 January 2026

The shares are overvalued as investors are overly excited about defence and gold exposure.

Esther Holloway | 12 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,151.80	0.10	0.00%
CAC 40	8,349.20	2.00	0.02%
DAX 40	25,302.70	117.96	-0.46%
Dow JONES (US)	49,065.45	126.54	-0.26%
FTSE 100	10,164.92	27.57	0.27%
HKSE	26,999.81	151.34	0.56%
NASDAQ	23,444.33	265.54	-1.12%
Nikkei 225	54,341.23	792.07	1.48%
NZX 50 Index	13,757.71	101.66	0.74%
S&P 500	6,916.32	47.42	-0.68%
S&P/ASX 200	8,820.60	1.20	-0.01%
SSE Composite Index	4,126.09	12.67	-0.31%